PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32618744-4	2021	In the last few years HER2/neu, folic acid-alpha (FRalpha) and Trop-2 overexpression have been exploited as excellent targets by novel ADCs such as Trastuzumab emtansine (T-DM1), SYD985, IMGN853 (Mirvetuximab soravtansine) and Sacituzumab govitecan (SG, IMMU-132) in multiple tumors including ovarian, endometrial and cervical cancers.	Folic Acid	32-42	rabaptin, RAB GTPase binding effector protein 2	Homo sapiens	50-57